SCC HOLDINGS BERHAD
KLSE (MYR): SCC (0158)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.245
Today's Change
0.00 (0.00%)
Day's Change
0.00 - 0.00
Trading Volume
0
Financial
T4Q
31-Mar-2021
2020
31-Mar-2021
2019
31-Mar-2021
2018
31-Mar-2021
2017
31-Mar-2021
Total assets
238
-1.64%
1000
+11.55%
110
+81.66%
900
-13.16%
600
+235.36%
Total current assets
238
1000
110
900
600
Cash & equivalents
238
1000
110
900
600
Short term investments
238
1000
110
900
600
Total receivables, net
238
1000
110
900
600
Accounts receivable - trade, net
238
1000
110
900
600
Other receivables
238
1000
110
900
600
Total inventory
238
1000
110
900
600
Inventories - work in progress
238
1000
110
900
600
Inventories - progress payments & other
238
1000
110
900
600
Inventories - finished goods
238
1000
110
900
600
Inventories - raw materials
238
1000
110
900
600
Total non-current assets
238
1000
110
900
600
Long term investments
238
1000
110
900
600
Note receivable - long term
238
1000
110
900
600
Investments in unconsolidated subsidiaries
238
1000
110
900
600
Other investments
238
1000
110
900
600
Net property/plant/equipment
238
1000
110
900
600
Gross property/plant/equipment
238
1000
110
900
600
Accumulated depreciation, total
238
1000
110
900
600
Deferred tax assets
238
1000
110
900
600
Net intangible assets
238
1000
110
900
600
Other current assets, total
238
1000
110
900
600
Total liabilities
238
-1.64%
1000
+11.55%
110
+81.66%
900
-13.16%
600
+235.36%
Total current liabilities
-238
-1000
-110
-900
-600
Total non-current liabilities
-238
-1000
-110
-900
-600
Long term debt
238
1000
110
900
600
Long term debt excl. lease liabilities
238
1000
110
900
600
Capital and operating lease obligations
238
1000
110
900
600
Provision for risks & charge
-238
-1000
-110
-900
-600
Deferred tax liabilities
-238
-1000
-110
-900
-600
Other liabilities, total
-238
-1000
-110
-900
-600
Total equity
-238
-1.64%
-1000
+11.55%
-110
+81.66%
-900
-13.16%
-600
+235.36%
Total liabilities & shareholders' equities
238B
1000B
110B
900B
600B
Total debt
238
1000
110
900
600
Book value per share
-238
-1000
-110
-900
-600
Discussions
5 people like this. Showing 50 of 295 comments
Hi, I didn't realize that SCC has undergone share split and bonus issue, and it's not reflected in the latest QR, so the calculation of net current asset value is incorrect. I have removed my comment to avoid misleading others.
2017-11-11 23:19
this stock is a dividend stock. If you hope for capital gain you will be disappointed because a majority of the company's earnings are distributed to s/h in form of dividends hence less money for reinvestment. This reinvestment money is essential to fund future growth. Plus the market cap is merely RM76 million, ultra low market cap will not attract institutional funds which are essential to push up the price further. PE of 12.6 is almost reaching the average small market cap index PE. this stock is purely dividen play giving out about 5-6% yield per annum. Anyway this is newbie brief analysis, I dont dig deeper into the company fundamentals so others might have much better insights than I am.
2018-01-17 14:29
this counter still alive? good qr but still no body want it.. so bad..
2018-03-01 12:16
This is a stable dividend stock. If u r buying at this current price,0.5. You are able to gain more than 6.5% on dividend Yield, which is much more better than a FD. Assuming the dividend maintained and increases every semi-annual.
2018-08-10 17:30
Day 59 of Fundamental Daily, YAPSS will be covering SCC Holdings Berhad's fundamental via a short animated video. I hope it helps and please enjoy the video, see ya! #YAPSS #FundamentalDaily #SCCHoldingsBerhad
Click the on the link to find out more: https://youtu.be/rJq51PiFmT0
2019-05-01 22:54
YAPSS Quick Summary and Free 10 Years Financial Data of SCC Holdings Berhad:
https://www.yapss.com/forum/klse-forum/scc-holdings-berhad-scc-0158
2019-12-13 19:37
United Arab Emirates Claims China’s Sinopharm Vaccine Is 100% Effective At Preventing Moderate And Severe Covid-19
TOPLINE The experimental vaccine developed by China National Pharmaceutical Group, also known as Sinopharm, is 86% effective at preventing Covid-19 infection and 100% effective at preventing severe and moderate disease, health officials from the United Arab Emirates announced Wednesday, although with scarce detail provided about the trial.
The UAE health ministry cited an interim analysis of a late-stage clinical trial involving 31,000 volunteers as the source of its information, though neither they nor Sinopharm provided any data from the trial to validate the claims such as how many participants were infected or how many actually received the vaccine.
The ministry said “no serious safety concerns” were observed, though, again, no information on side effects was provided.
The ministry said the announcement is a “significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine.”
The ministry added that it had officially registered the vaccine at the request of the manufacturer, which it says could eventually lead to the shot’s widespread authorization.
https://www.forbes.com/sites/roberthart/2020/12/09/united-arab-emirates-claims-chinas-sinopharm-vaccine-is-100-effective-at-preventing-moderate-and-severe-covid-19/?sh=2a60fb42595ca
2020-12-10 00:16
This counter has very little ticket : 141 million only. Very easy to goreng if they want to.
2021-04-01 18:10
Average target price : RM 2.69. ; Ticket: 141 million only ; Annual financial reports never lose since 2011 ; Why the present market price so low ?
2021-04-05 07:23
It started to fry. Hopefully keeps frying this coming Monday. Non-stop frying !
2021-07-25 17:10
Post a Comment
Featured Posts
Latest Videos
Apps
Top Articles
1
Good Articles to Share
2
3
Mercury Securities Research
4
Koon Yew Yin's Blog
5
BFM Podcast
6
7
BFM Podcast
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
prescott2006
cash a lot but those old folks haven't figure out a way to boost their business.
2017-05-30 22:29